XIENCE V™ Wins United States Approval
During a stent procedure, a stent such as XIENCE V is placed over a small
balloon. A doctor then uses a catheter to guide the balloon and stent through
the femoral artery to the narrowed or blocked section of the coronary
artery. 
XIENCE V acts as a scaffolding to prop open clogged arteries and releases the drug everolimus in a controlled fashion to prevent the artery from becoming narrowed again. |
Abbott's XIENCE V drug eluting stent is now available in the United States for the treatment of coronary artery disease, following the July 2, 2008 approval by the U.S. Food and Drug Administration. The XIENCE V drug coated stent treats coronary artery disease by propping open a narrowed or blocked artery and releasing the drug, everolimus, in a controlled manner to prevent the artery from becoming blocked again following a stent procedure. Coronary artery disease occurs when plaque build-up narrows the arteries and reduces blood flow to the heart, which can lead to chest pain or a heart attack.
Additional Information:
- Learn more about the XIENCE V Drug Eluting Stent in this Abbott animation:
- Learn how vulnerable plaque formation and rupture can lead to a heart attack in this Abbott animation:
- Press release: July 2, 2008
FDA Approves Abbott's XIENCE™ V Drug Eluting Stent
AP2925472 Rev. D
